Chronic Obstructive Pulmonary Disease affects up to 210 million people worldwide.

1 in 10 adults aged 40 years and older have moderate COPD or worse (GOLD grade 2 or higher).

Projected to be the 3rd leading cause of death by 2020.

Symptoms of COPD are often inadequately controlled by bronchodilator monotherapy. LAMAs and LABAs have different pathways leading to bronchodilation.

IGNITE is one of the LARGEST international Phase III clinical trial programs exploring QVA149 for the treatment of COPD.